- Home
- JGH vs PRQR Comparison
JGH vs PRQR Comparison
Compare JGH & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JGH | PRQR |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.3M | 250.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | JGH | PRQR |
|---|---|---|
| Price | $12.45 | $2.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.14 |
| AVG Volume (30 Days) | 73.9K | ★ 621.8K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.36 | $1.07 |
| 52 Week High | $12.85 | $3.10 |
Technical Indicators
Market Signals| Indicator | JGH | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 46.39 |
| Support Level | $12.39 | $2.03 |
| Resistance Level | $12.50 | $2.25 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 29.97 | 40.00 |
Price Performance
Historical ComparisonAbout JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.